# Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT07222566** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1410 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Metastatic Non Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **BIOLOGICAL:** PF-08634404
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Chemotherapy Regimen 1
- **DRUG:** Chemotherapy Regimen 2

## Key facts

- **NCT ID:** NCT07222566
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2029-02-27
- **Final completion:** 2032-08-26
- **Target enrollment:** 1410 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222566, "Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07222566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*